What is the significance of mismatch repair deficiency in stage IV colon cancer?
作者信息
Sugiura Kiyoaki
机构信息
Department of Surgery, Eiju General Hospital, Tokyo, Japan.
出版信息
J Gastrointest Oncol. 2025 Feb 28;16(1):330-332. doi: 10.21037/jgo-2025-74. Epub 2025 Feb 25.
Abstract
摘要
相似文献
1
What is the significance of mismatch repair deficiency in stage IV colon cancer?错配修复缺陷在IV期结肠癌中的意义是什么？
J Gastrointest Oncol. 2025 Feb 28;16(1):330-332. doi: 10.21037/jgo-2025-74. Epub 2025 Feb 25.
2
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.辅助 FOLFOX 治疗后结直肠癌中微卫星不稳定性的临床影响。
Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.
3
Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series.鉴定错配修复缺陷型结直肠癌：在一项大型基于人群的系列研究中，免疫组织化学与微卫星不稳定性检测具有近乎完美的一致性。
Histopathology. 2021 Feb;78(3):401-413. doi: 10.1111/his.14233. Epub 2020 Oct 11.
4
[Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].[子宫内膜癌分子分类中错配修复及微卫星不稳定性状态的综合评估]
Zhonghua Fu Chan Ke Za Zhi. 2023 Oct 25;58(10):755-765. doi: 10.3760/cma.j.cn112141-20230711-00316.
5
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.辅助治疗后疾病复发的微卫星不稳定和/或错配修复缺陷 III 期结肠癌患者的预后：来自七个研究的 ACCENT 汇总分析的结果。
Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.
6
Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.错配修复/微卫星不稳定不一致型子宫内膜癌的特征。
Cancer. 2024 Feb 1;130(3):385-399. doi: 10.1002/cncr.35030. Epub 2023 Sep 26.
7
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.DNA 错配修复（MMR）状态对奥沙利铂为基础的一线化疗治疗复发性或转移性结直肠癌的影响。
Med Oncol. 2010 Dec;27(4):1277-85. doi: 10.1007/s12032-009-9374-x. Epub 2009 Dec 1.
8
Mismatch repair deficiency confers worse survival in stage IV colon cancer.错配修复缺陷导致IV期结肠癌患者的生存率更低。
J Gastrointest Oncol. 2024 Dec 31;15(6):2521-2532. doi: 10.21037/jgo-24-387. Epub 2024 Dec 28.
9
Evaluation of Concordance Between Deficient Mismatch Repair and Microsatellite Instability Testing and Their Association with Clinicopathological Features in Colorectal Cancer.结直肠癌中错配修复缺陷与微卫星不稳定性检测之间的一致性评估及其与临床病理特征的关联
Cancer Manag Res. 2020 Apr 24;12:2863-2873. doi: 10.2147/CMAR.S248069. eCollection 2020.
10
[Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].[结直肠癌错配修复蛋白表达：3428例回顾性分析]
Zhonghua Bing Li Xue Za Zhi. 2021 Apr 8;50(4):369-375. doi: 10.3760/cma.j.cn112151-20200731-00608.
本文引用的文献
1
Mismatch repair deficiency confers worse survival in stage IV colon cancer.错配修复缺陷导致IV期结肠癌患者的生存率更低。
J Gastrointest Oncol. 2024 Dec 31;15(6):2521-2532. doi: 10.21037/jgo-24-387. Epub 2024 Dec 28.
2
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.帕博利珠单抗对比化疗用于微卫星高度不稳定或错配修复缺陷的转移性结直肠癌：III期随机KEYNOTE-177研究的5年随访结果
Ann Oncol. 2025 Mar;36(3):277-284. doi: 10.1016/j.annonc.2024.11.012. Epub 2024 Dec 2.
3
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹木单抗治疗微卫星不稳定高转移性结直肠癌。
N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
4
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.可切除结肠癌的术前化疗：一项国际随机对照试验的成熟结果。
J Clin Oncol. 2023 Mar 10;41(8):1541-1552. doi: 10.1200/JCO.22.00046. Epub 2023 Jan 19.
5
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.转移性结直肠癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25.
6
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.转移性结直肠癌的治疗：ASCO 指南。
J Clin Oncol. 2023 Jan 20;41(3):678-700. doi: 10.1200/JCO.22.01690. Epub 2022 Oct 17.
7
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.帕博利珠单抗与化疗治疗微卫星高度不稳定或错配修复缺陷转移性结直肠癌（KEYNOTE-177）：一项随机、开放标签、III 期研究的最终分析。
Lancet Oncol. 2022 May;23(5):659-670. doi: 10.1016/S1470-2045(22)00197-8. Epub 2022 Apr 12.
8
Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer.错配修复缺陷在非转移性结直肠癌中的预后和预测价值
Cancers (Basel). 2021 Jan 15;13(2):300. doi: 10.3390/cancers13020300.
9
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
10
Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis.真实人群中转移性结直肠癌患者死亡的预测：一项多中心探索性分析。
BMC Cancer. 2020 Nov 25;20(1):1149. doi: 10.1186/s12885-020-07656-w.
Zotero 插件